Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264964 | 0.80 | USP7 (0.58) | USP7PIK3CDNCF1LRRK2PSMB8 | |
| SCHEMBL12346384 | 0.77 | PSMB8 (0.48) | USP7PIK3CDNCF1LRRK2PSMB8 | |
| SCHEMBL1717834 | 0.77 | NEK1 (0.53) | NCF1LRRK2PSMB8CNR1CNR2 | |
| SCHEMBL26686378 | 0.74 | JAK2 (0.49) | USP7PIK3CDNCF1LRRK2PSMB8 | |
| SCHEMBL1690875 | 0.74 | ALDH1A1 (0.66) | NCF1PSMB8CNR1CNR2DRD2 | |
| SCHEMBL14988278 | 0.74 | NCF1 (0.53) | USP7PIK3CDNCF1LRRK2PSMB8 | |
| SCHEMBL16054137 | 0.74 | NCF1 (0.60) | USP7NCF1LRRK2PSMB8CNR1 | |
| SCHEMBL4937468 | 0.74 | HPGD (0.56) | PIK3CDLRRK2PLK4KDM4EHPGD | |
| SCHEMBL31240352 | 0.74 | TBK1 (0.61) | — | |
| SCHEMBL11196105 | 0.73 | NCF1 (0.83) | NCF1PSMB8NOS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| EP-1937680-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | claimed |
| CN-101321753-A | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | CN | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1937680-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, GSK3A, PYGB | USP7 3874/4885PIK3CD 639/4885NCF1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.